Download presentation: The importance of PPP to move new concepts into clinical development


In November 2012 over 200 delegates participated in the 13th Annual World Vaccine Congress Lyon in France. This event brings together vaccine leaders and policy makers from around the globe. Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Camille Locht,  ‘The importance of PPP to move new concepts into clinical development: The case of live attenuated pertussis vaccines.'

This focus of this study into Pertussis Vaccines is as follows:

  • First-in-man, dose-escalating, placebo-controlled, double blind, safety trial
    • Primary Objective
      -Assess general safety and local tolerability in the respiratory tract after single ascending dose of BPZE1
    • Secondary Objectives
      – Evaluate colonization of the human respiratory tract after a single ascending dose of BPZE1
      – Evaluate T and B cell immune responses to B. pertussis after a single ascending dose of BPZE1

Download the full presentation here >

For more information about this and other topics discussed at the World Vaccine Congress Europe, subscribe to the Vaccine Nation newsletter, or visit the event website.

For more updates on the vaccines industry, follow us on Twitter: @vaccinenation or join our LinkedIn group: Vaccine Nation

Comments 1

Leave a Reply

Your email address will not be published. Required fields are marked *